Literature DB >> 21156225

Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.

Nyla A Heerema1, John C Byrd, Paola S Dal Cin, Marie L Dell' Aquila, Prasad R K Koduru, Ayala Aviram, Stephanie A Smoley, Laura Z Rassenti, Andrew W Greaves, Jennifer R Brown, Kanti R Rai, Thomas J Kipps, Neil E Kay, Daniel L Van Dyke.   

Abstract

Cytogenetic abnormalities are important prognostic indicators in CLL. Historically, only interphase cytogenetics was clinically useful in CLL, because traditional mitogens are not effective mitotic stimulants. Recently, CpG-oligodeoxynucleotide (ODN) stimulation has shown effectiveness in CLL cells. The CLL Research Consortium tested the effectiveness and reproducibility of CpG-ODN stimulation for detecting chromosomally abnormal clones by five laboratories. More clonal abnormalities were observed after culture of CLL cells with CpG-ODN than with the traditional pokeweed mitogen plus 12-O-tetradecanoylphorbol-13-acetate (PWM+TPA). All clonal abnormalities in PWM+TPA cultures were observed in CpG-ODN cultures, whereas CpG-ODN identified some clones not found by PWM+TPA. CpG-ODN stimulation of one normal control sample and 12 CLL samples showed that, excepting clones of del(13q) in low frequencies and one translocation, results in all five laboratories were consistent, and all abnormalities were concordant with FISH. Abnormal clones in CLL were more readily detected with CpG-ODN stimulation than with traditional B-cell mitogens. With CpG-ODN stimulation, abnormalities were reproducible among cytogenetic laboratories. CpG-ODN did not appear to induce aberrations in cell culture, but did enhance detection of abnormalities and complexity in CLL. Because karyotypic complexity is prognostic and is not detectable by standard FISH analyses, stimulation with CpG-ODN is useful for identifying this additional prognostic factor in CLL.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156225      PMCID: PMC3018693          DOI: 10.1016/j.cancergencyto.2010.07.128

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  27 in total

1.  CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.

Authors:  R Buhmann; A Nolte; D Westhaus; B Emmerich; M Hallek
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

2.  Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.

Authors:  Kimberly J Stockero; Stephanie R Fink; Stephanie A Smoley; Sarah F Paternoster; Tait D Shanafelt; Timothy G Call; Clive S Zent; Daniel L Van Dyke; Neil E Kay; Gordon W Dewald
Journal:  Cancer Genet Cytogenet       Date:  2006-04-15

3.  Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel.

Authors:  K S Reddy
Journal:  Br J Haematol       Date:  2006-03       Impact factor: 6.998

4.  Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities.

Authors:  S Struski; C Gervais; C Helias; R Herbrecht; B Audhuy; L Mauvieux
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

5.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Authors:  John C Byrd; John G Gribben; Bercedis L Peterson; Michael R Grever; Gerard Lozanski; David M Lucas; Ben Lampson; Richard A Larson; Michael A Caligiuri; Nyla A Heerema
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

Review 6.  Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia.

Authors:  S Stilgenbauer; K Döhner; M Bentz; P Lichter; H Döhner
Journal:  Ann Hematol       Date:  1998 Mar-Apr       Impact factor: 3.673

7.  Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.

Authors:  Frank Dicker; Susanne Schnittger; Torsten Haferlach; Wolfgang Kern; Claudia Schoch
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

8.  Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Authors:  Thomas S Lin; Kristie A Blum; Diane Beth Fischer; Sarah M Mitchell; Amy S Ruppert; Pierluigi Porcu; Eric H Kraut; Robert A Baiocchi; Mollie E Moran; Amy J Johnson; Larry J Schaaf; Michael R Grever; John C Byrd
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

9.  Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion.

Authors:  Joanna M Ilvesaro; Melinda A Merrell; Li Li; Savita Wakchoure; David Graves; Sonja Brooks; Eeva Rahko; Arja Jukkola-Vuorinen; Katri S Vuopala; Kevin W Harris; Katri S Selander
Journal:  Mol Cancer Res       Date:  2008-10       Impact factor: 5.852

10.  Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: A Belgian multicentric study.

Authors:  Natalie Put; Peter Konings; Katrina Rack; Mauricette Jamar; Nadine Van Roy; Jeanne-Marie Libouton; Pascal Vannuffel; Daniel Sartenaer; Geneviève Ameye; Frank Speleman; Christian Herens; Hélène A Poirel; Yves Moreau; Anne Hagemeijer; Peter Vandenberghe; Lucienne Michaux
Journal:  Genes Chromosomes Cancer       Date:  2009-10       Impact factor: 5.006

View more
  12 in total

1.  Jumping translocations, a novel finding in chronic lymphocytic leukaemia.

Authors:  Cecelia R Miller; Deborah Stephens; Amy S Ruppert; Frederick Racke; Andrew McFaddin; Heather Breidenbach; Huey-Jen Lin; Kathy Waller; Tammy Bannerman; Jeffrey A Jones; Jennifer A Woyach; Leslie A Andritsos; Kami Maddocks; Weiqiang Zhao; Gerard Lozanski; Joseph M Flynn; Michael Grever; John C Byrd; Nyla A Heerema
Journal:  Br J Haematol       Date:  2015-04-19       Impact factor: 6.998

2.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Authors:  Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Thomas M Habermann; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Lynn Wilson; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

3.  Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.

Authors:  Deborah M Stephens; Amy S Ruppert; William G Weirda; Jeffrey A Jones; Jennifer A Woyach; Kami Maddocks; Samantha M Jaglowski; Leslie A Andritsos; Joseph M Flynn; Michael R Grever; Gerard Lozanski; Constantine Tam; Susan O'Brien; Michael J Keating; Natarajan Muthusamy; Lynne V Abruzzo; Nyla A Heerema; John C Byrd
Journal:  Am J Hematol       Date:  2015-10-12       Impact factor: 10.047

Review 4.  Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.

Authors:  Ayed O Ayed; Sameer A Parikh
Journal:  Leuk Lymphoma       Date:  2017-11-08

Review 5.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

6.  CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Fiona Pui San Liaw; Lai Ching Lau; Alvin Soon Tiong Lim; Tse Hui Lim; Geok Yee Lee; Sim Leng Tien
Journal:  Int J Hematol       Date:  2014-10-10       Impact factor: 2.490

7.  Section E6.1-6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow-acquired chromosomal abnormalities.

Authors:  Fady M Mikhail; Nyla A Heerema; Kathleen W Rao; Rachel D Burnside; Athena M Cherry; Linda D Cooley
Journal:  Genet Med       Date:  2016-04-28       Impact factor: 8.822

8.  Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma.

Authors:  Antonella Bardi; Francesco Cavazzini; Gian Matteo Rigolin; Elisa Tammiso; Eleonora Volta; Elisa Pezzolo; Luca Formigaro; Olga Sofritti; Giulia Daghia; Cristina Ambrosio; Lara Rizzotto; Awad E Abass; Fiorella D'Auria; Pellegrino Musto; Antonio Cuneo
Journal:  J Biomed Biotechnol       Date:  2011-05-21

9.  Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center.

Authors:  D M Stephens; A S Ruppert; J A Jones; J Woyach; K Maddocks; S M Jaglowski; L A Andritsos; J M Flynn; M R Grever; G Lozanski; A J Johnson; N Muthusamy; N A Heerema; J C Byrd
Journal:  Leukemia       Date:  2014-01-23       Impact factor: 11.528

Review 10.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.